单次全肝Y90放射栓塞治疗多灶性HCC的可行性
回顾性纳入37例Child-Pugh A级多灶性肝细胞癌患者,评估单次全肝Y90放射栓塞的可行性、安全性与疗效。3个月客观缓解率为78.4%,疾病控制率为94.6%,51.4%实现成功降期。未见3/4级不良事件或放射性肝病,提示在经选择患者中该方案可作为一种桥接根治性手术的手段。
要点
- 单次全肝Y90放射栓塞适用于无实质肝脏可保留的Child-Pugh A级多灶性HCC患者
- 该方案可见较高客观缓解率与降期率,部分患者后续接受切除或肝移植
- 术后需关注Child-Pugh分级变化及腹水,本组未观察到3/4级不良事件
核心结论
- 单次全肝Y90放射栓塞在经严格选择的Child-Pugh A级多灶性HCC患者中可行,肝脏安全性可接受。
- 该方案可获得较高缓解率和降期率,在部分患者中可作为桥接根治性手术的选项。
研究设计与样本
- 回顾性研究,纳入2017—2024年37例多灶性HCC患者,中位年龄60岁,肿瘤数目2—21个(中位9个)。
- 纳入标准为Child-Pugh A级且治疗前影像和血管造影评估无实质肝脏可保留者。
- 治疗计划基于99mTc-MAA SPECT及分区模型剂量学制定。
诊断标准与关键数值
- 3个月客观缓解率为78.4%,疾病控制率为94.6%,完全缓解见于11例患者(29.7%)。
- 19例患者(51.4%)实现成功降期,11例(29.7%)后续接受手术,包括1例切除和10例活体肝移植。
- 中位无进展生存期为23.5个月,2年总生存率为78.3%,2年无进展生存率为46.8%。
临床应用与阅片要点
- 治疗前影像与血管造影评估用于确认无实质肝脏可保留,是选择单次全肝方案的关键步骤。
- 99mTc-MAA SPECT和分区模型剂量学用于制定单次全肝Y90治疗计划。
- 术后3—6个月内应随访Child-Pugh分级变化和腹水发生,以评估肝脏毒性。
- 本组中1例肝硬化患者出现Child-Pugh分级恶化和腹水,提示肝硬化背景需谨慎监测。
局限性
- 回顾性单中心设计与样本量较小,可能影响结果外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the feasibility, safety, and treatment outcomes of single-session whole-liver yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with multifocal hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: This retrospective study included 37 patients (age, 23-86 years; median age, 60 years) with multifocal HCC (2-21 tumors; median, 9) and preserved liver function (Child-Pugh A) who underwent planned single-session whole-liver Y90 TARE between 2017 and 2024. Treatment was performed when no substantial liver parenchyma could be spared on pretreatment imaging and angiographic evaluation. Treatment planning was based on the findings of technetium-99m macroaggregated albumin single-photon emission computed tomography and partition-model dosimetry. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Overall survival, progression-free survival, and hepatic toxicity were also evaluated, with toxicity assessed on the basis of the occurrence of adverse events, Child-Pugh class change, and the development of ascites within 3-6 months.
RESULTS: Patients were followed up for 1.4-49.0 months (median, 17.8 months). At 3 months, the objective response rate was 78.4%; the disease control rate was 94.6%; and complete response was noted in 11 patients (29.7%). Successful downstaging was achieved in 19 (51.4%) patients. The median overall survival was not reached, and the median progression-free survival was 23.5 months. The 2-year overall and progression-free survival rates were 78.3% and 46.8%, respectively. Eleven patients (29.7%) subsequently underwent surgery, including one resection and 10 living-donor liver transplantations. None of the patients showed grade 3 or 4 adverse events or radioembolization-induced liver disease. One patient with cirrhosis showed worsening of the Child-Pugh class with ascites.
CONCLUSION: Single-session whole-liver Y90 TARE was feasible and showed acceptable hepatic safety in carefully selected patients with multifocal HCC and preserved liver function. It achieved high response and downstaging rates and may serve as a bridge to curative surgery in selected patients.
引用
- Huang, Ou, Tsang, et al. Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma. Korean J Radiol. 2026. PMID: 42683641. doi:10.3348/kjr.2026.0364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。